Melanoma: is immunotherapy the future?. (April 2013)

• Record Type: Journal Article
• Authors: Weber, Jeffrey S
• Is Part Of: Expert review of dermatology. Volume 8:Number 2(2013)
• Page Start: 119
• Page End: 121
• Publication Date: 2013-04
• Subjects: Dermatology -- Periodicals; 616.5005
• DOI: 10.1586/edm.13.14
• Languages: English
• ISSNs: 1746-9872

Abstract

Interview by Jenaid Rees, Commissioning Editor Jeffrey S Weber, MD, PhD, is the current Director of the Donald A Adam Comprehensive Melanoma Research Center of Excellence and is a senior member at the Moffitt Cancer Center (Tampa, FL, USA). After achieving his PhD in molecular cell biology from Rockefeller University (NY, USA) and then a medical degree from New York University Medical Center (NY, USA), Dr Weber went on to complete a residency in internal medicine for the University of California, San Diego (CA, USA) before undertaking his fellowships at the National Cancer Institute (MD, USA). His main clinical interest involves immunotherapy for melanoma and other malignancies, and he has been working in the field of melanoma therapeutics for over 20 years. In this time, he has published more than 120 articles in peer reviewed journals and has served on several scientific boards including the Melanoma Research Foundation Scientific Advisory Committee and the scientific advisory board of the Melanoma Therapeutics Foundation. He has been peer review funded continuously by the NIH for over 18 years and has held over a dozen investigational new drug applications with the US FDA.